Navigation Links
Ultragenyx Relocates Company Headquarters to Support Operational Expansion
Date:4/23/2012

NOVATO, Calif., April 23, 2012 /PRNewswire/ -- Ultragenyx Pharmaceutical Inc., a biotechnology company focused on developing treatments for rare and ultra-rare genetic disorders, today announced that it has moved its corporate headquarters to a larger facility in the Bel Marin Keys area of Novato, CA.  The relocation will accommodate current and future growth of Ultragenyx' staff and expand operations in the areas of clinical development, regulatory affairs, technical operations, and administration.  The company will continue to lease laboratory facilities at the Buck Institute in Novato which currently houses the company's research staff.

"Our move to our new corporate headquarters will enable us to support the advancement of our pipeline of treatments for rare and ultra-rare diseases and grow our team as needed," said Emil Kakkis, MD, PhD, Chief Executive Officer, who founded Ultragenyx in 2010.  "We want to express our appreciation to the elected officials and city of Novato for their support of Ultragenyx, and we look forward to continuing to be an integral part of the Novato community."

Ultragenyx will celebrate the relocation of its corporate headquarters by holding a ribbon-cutting ceremony on Friday, April 27, 2012, at 3:30pm at its new location. 

The address of the new corporate headquarters is 60 Leveroni Court, Novato, CA 94949, and the new corporate phone number is 415-483-8800.

About Ultragenyx

Ultragenyx is a privately held, developmental stage biotechnology company committed to bringing life-enhancing therapeutics for patients with rare and ultra-rare genetic diseases, also known as orphan and ultra-orphan diseases, to market.  The company focuses on rare metabolic diseases that affect small numbers of patients, but for which the unmet medical need is high and there are no effective treatments.  Ultragenyx intends to build a sustainable pipeline of safe and effective the
'/>"/>

SOURCE Ultragenyx Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Ultragenyx Granted Orphan Designations in Europe for Two Lead Product Candidates, UX001 for HIBM and UX003 for MPS 7
2. Ultragenyx Appoints Tom Kassberg as Chief Business Officer and Announces Management Team
3. Ultragenyx Granted Orphan Drug Designation for UX001 SA-ER for the Treatment of Hereditary Inclusion Body Myopathy (HIBM)
4. Ultragenyx Initiates Phase 1 Clinical Study of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Muscle Wasting Disease
5. TheraBiogen, Inc. Relocates Corporate Headquarters to New Jersey
6. Rochester Medical Implants Relocates to New Facility in Noblesville, IN
7. The Pittsburgh Life Sciences Greenhouse Relocates Therapeutics Company to Pittsburgh
8. Pharmaceutical Industry Service Company Awarded The UKs Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade
9. KPMG Survey: Medical Device Execs Say New Excise Tax Will Hit Their Company Bottom Lines Hard
10. Puritan Medical Products Company Launches New Diagnostic Collection and Transport Systems
11. Global Fund Celebrates Efforts of Partners Chevron, The Coca-Cola Company, (RED) and PEPFAR at Capitol Hill Event
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Astellas has appointed James Kellerman ... the Americas. Kellerman will report directly to Linda ... Astellas. In his new role, Kellerman will lead a ... and manage the region,s intellectual property matters, coordinating closely ... very pleased to welcome Jim to Astellas. Jim brings ...
(Date:9/2/2014)... Sept. 2, 2014  Numotion is pleased to announce the ... of Directors. Mark is a 30-year retired ... positions across the organization and was a GE Company Officer ... Mark spent many years running business units within GE Healthcare, ... Healthcare Americas. "We are delighted to welcome ...
(Date:9/2/2014)... , Sept. 2, 2014  On July 31, ... to Congress that it is moving forward to regulate ... the minutes until laboratories throughout the U.S. will need ... Although some medical laboratories may subscribe to the ... FDA to put guidelines in place, it,s widely acknowledged ...
Breaking Medicine Technology:Leading Intellectual Property Counsel, James Kellerman, Joins Astellas as Vice President 2FDA Tells Congress It Intends to Regulate LDTs! Web Conference to Provide Straight Talk on Essential Steps Clinical Laboratories and Pathology Groups Will Need to Take to Comply 2FDA Tells Congress It Intends to Regulate LDTs! Web Conference to Provide Straight Talk on Essential Steps Clinical Laboratories and Pathology Groups Will Need to Take to Comply 3
... Solutions Development Company (MSDC), a drug discovery and ... metabolic diseases, announced today that it has launched ... second drug candidate for the treatment of type ... placebo-controlled clinical trial will involve approximately 125 patients ...
... SAN and NYSE: SNY ) announced today ... Rights (CVRs) offered to Genzyme shareholders as part of ... by the U.S. Securities and Exchange Commission. ... Genzyme, sanofi-aventis has commenced an exchange offer to acquire ...
Cached Medicine Technology:Metabolic Solutions Development Company Launches Phase 2a Trial of Its Second Compound to Treat Type 2 Diabetes 2Sanofi-aventis Announces Registration Statement for CVR Related to Genzyme Acquisition Declared Effective 2Sanofi-aventis Announces Registration Statement for CVR Related to Genzyme Acquisition Declared Effective 3
(Date:9/2/2014)... Evolve Medical Clinics, the first ... urgent care arena, is having its Grand Opening ... health fair the clinic is sponsoring. Evolve offers ... patients in achieving high quality, convenient medical care. ... is a groundbreaking change in healthcare. The membership ...
(Date:9/2/2014)... September 02, 2014 Last year, SIGVARIS ... with the launch of a luxurious line of graduated compression ... the SEA ISLAND COTTON Socks are joining the SIGVARIS MEDICAL ... more people the comfort of natural cotton fibers. , ... are surprised to find socks as soft as the finest ...
(Date:9/2/2014)... Ticket Down is a reputable source ... September will be an exciting week for soccer fans in ... Ecuador and Bolivia will battle on U.S. soil in friendly ... September 5th - September 9th: , Brazil vs. Ecuador ... Mexico vs. Chile Tickets at Levi's Stadium on ...
(Date:9/2/2014)... 02, 2014 The exclusive ClinicCRM patient ... designed to help doctors manage foreign patient flow, enable ... conversion rates and clink revenue. Since its launch in ... in sales revenue and a 70 percent increase in ... their own healthcare practices. , With its ease of ...
(Date:9/2/2014)... but your outpatient doctor does not know? Or ... care, but your doctor does not have the ... or incomplete communication from hospitals to outpatient primary ... and lead to hospital readmissions. , However, ... improve hospitals, communication during patient care transitions. Researchers ...
Breaking Medicine News(10 mins):Health News:Evolve Medical Clinics Announces Grand Opening of Annapolis, Maryland Location 2Health News:Evolve Medical Clinics Announces Grand Opening of Annapolis, Maryland Location 3Health News:SIGVARIS’ Luxury Line of Compression Socks, SEA ISLAND COTTON, Now Available in Stronger Compression Level 2Health News:Ticket Down Substantially Slashes Ticket Prices on Brazil vs. Ecuador Tickets, Brazil vs. Colombia Tickets, Mexico vs. Chile Tickets and Mexico vs. Bolivia Tickets 2Health News:Ticket Down Substantially Slashes Ticket Prices on Brazil vs. Ecuador Tickets, Brazil vs. Colombia Tickets, Mexico vs. Chile Tickets and Mexico vs. Bolivia Tickets 3Health News:Doctors Abroad Using VisitandCare.com Patient Management Software Report 60% Increase in Revenue 2Health News:Doctors Abroad Using VisitandCare.com Patient Management Software Report 60% Increase in Revenue 3Health News:Doctors Abroad Using VisitandCare.com Patient Management Software Report 60% Increase in Revenue 4Health News:Can data motivate hospital leaders to improve care transitions? 2
... implications of the Clinical Antipsychotic Trials of Intervention ... antipsychotic medication perphenazine// was less expensive and no ... used in the trial during initial treatment, suggesting ... treating schizophrenia. The study, published in the American ...
... has shown that a new compound may improve the fertility ... percentage sperm motility. ,The sperm from male smokers ... there was a doubling in the fertilizing capacity of sperm ... Ph.D., and colleagues presented the findings at the 2006 meeting ...
... The world has heard of the illustrious mathematician and physicist, ... of Relativity’. But did you know that Albert Einstein suffered ... three years old? Einstein also had a problem with Maths ... a world famous Mathematician, it is undoubtedly, the will to ...
... intensive care doctors are responsible for large cost variations ... the intensive care unit (ICU), higher resource// use has ... mortality. ,This research appears in the first ... Respiratory and Critical Care Medicine, published by the American ...
... once treated mainly elderly patients for health problems such ... younger patients who have the same ailments. ... Proceedings focuses on the increasing prevalence of metabolic syndrome, ... obesity, high blood pressure and abnormal levels of glucose ...
... fallen drastically, and the rate of decline has improved considerably ... of data// from the National Long-Term Care Survey (NLTCS). The ... of Sciences, has revealed that the severe disability among the ... 1982 to 19 percent in 2004/2005. ,The study ...
Cached Medicine News:Health News:Older Medication May Be More Cost-Effective for Some Schizophrenia Patients 2Health News:New Compound May Improve Fertility in Smokers 2Health News:New Compound May Improve Fertility in Smokers 3Health News:Equal Opportunity for the Disabled 2Health News:Large Variations in Cost Has No Effect on Length of Stay or Mortality 2Health News:Large Variations in Cost Has No Effect on Length of Stay or Mortality 3Health News:Treating Obesity Vital for Public Health, Physicians Say 2Health News:Disability Factor Among Older Americans Shows Improvement 2
The Tag-It™ Cystic Fibrosis ASR reagents can be used by high complexity CLIA approved laboratories for detection of up to 70 mutations and 6 variants (polymorphisms) in the cystic fibrosis tran...
The Tag-It™ Cystic Fibrosis ASR reagents can be used by high complexity CLIA approved laboratories for detection of up to 70 mutations and 6 variants (polymorphisms) in the cystic fibrosis tran...
... The BreatheX is a wearable CPAP ... treatment of sleep apnea. The lightweight BreatheX ... of therapy with its built-in, rechargeable battery, ... users will no longer need to be ...
Shandon Paraffin Block Cartons...
Medicine Products: